Home: Artios Pharma

Artios - Experts in DDR

We are developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to selectively kill cancer cells

Find out how

Cancers change their DDR pathways to allow mutations in their DNA so that they can evolve and adapt. This enables cancers to become resistant to current therapies.

First-in-class

Artios aims to be the leading independent DDR company with a strong array of new cancer therapies in development. Our cutting-edge DDR programmes have potential applications across a broad range of cancers

Find out how

Targeting the DDR has been clinically validated through the recent success of PARP inhibitors and the launch of Lynparza™ (olaparib; AstraZeneca).

Developed by an expert team

Working together with industry-leading partners and investors to push the boundaries in the fight against cancer

Find out who

12:15 PM May 30thArtios Pharma CEO Niall Martin was featured in InVivo’s piece on “Biotech CEOs: Entrepreneurs who want to translate… https://t.co/jbjSBuNAQE
08:08 PM Mar 31stArtios Pharma are currently at the AACR Annual Meeting being held in Atlanta. Drs Niall Martin, Graeme Smith, Harry… https://t.co/fI9Lwutgbi
12:44 PM Mar 19thArtios Pharma is in Business Weekly’s Killer 50 companies. https://t.co/FNLF0V169M
02:52 PM Mar 13thDr Niall Martin, CEO of Artios Pharma is attending BioCapital in Amsterdam tomorrow, March 14th.
11:24 AM Nov 14th@artiospharma a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, wins the 201… https://t.co/uBfQPI8hYO

Our Partners

We have in-licensed lead programmes from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK) and we are working in collaboration with them and other world leaders in DDR to discover and develop exciting new programmes